Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

Nilotinib, interferon-alfa

Trial Locations (1)

Novartis Investigative Site, Leipzig